Talazoparib

Talazoparib (trade name Talzenna) is an orally available poly ADP ribose polymerase (PARP) inhibitor developed by Pfizer for the treatment of advanced breast cancer with germline BRCA mutations. Talazoparib is similar to the first in class PARP inhibitor, olaparib. It was approved in 2018 in the United States and 2019 in Europe for germline BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer.

Description

Talazoparib (trade name Talzenna) is an orally available poly ADP ribose polymerase (PARP) inhibitor developed by Pfizer for the treatment of advanced breast cancer with germline BRCA mutations. Talazoparib is similar to the first in class PARP inhibitor, olaparib. It was approved in 2018 in the United States and 2019 in Europe for germline BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer.

Additional information

CAS Number

Keywords

Molecular Formula

Molecular Weight


Notice: id was called incorrectly. Product properties should not be accessed directly. Backtrace: require('wp-blog-header.php'), require_once('wp-includes/template-loader.php'), include('/plugins/woocommerce/templates/single-product.php'), wc_get_template_part, load_template, require('/plugins/woocommerce/templates/content-single-product.php'), do_action('woocommerce_after_single_product_summary'), WP_Hook->do_action, WP_Hook->apply_filters, woocommerce_output_related_products, woocommerce_related_products, wc_get_template, include('/themes/stout/templates/woocommerce/single-product/related.php'), WC_Abstract_Legacy_Product->__get, wc_doing_it_wrong Please see Debugging in WordPress for more information. (This message was added in version 3.0.) in /var/www/wp-includes/functions.php on line 5313